AU2014228983B2 - Toxoid, compositions and related methods - Google Patents

Toxoid, compositions and related methods Download PDF

Info

Publication number
AU2014228983B2
AU2014228983B2 AU2014228983A AU2014228983A AU2014228983B2 AU 2014228983 B2 AU2014228983 B2 AU 2014228983B2 AU 2014228983 A AU2014228983 A AU 2014228983A AU 2014228983 A AU2014228983 A AU 2014228983A AU 2014228983 B2 AU2014228983 B2 AU 2014228983B2
Authority
AU
Australia
Prior art keywords
toxin
difficile
toxoid
purified
difficile toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014228983A
Other languages
English (en)
Other versions
AU2014228983A1 (en
Inventor
Mark Shieh
Mike SOIKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014228983(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of AU2014228983A1 publication Critical patent/AU2014228983A1/en
Application granted granted Critical
Publication of AU2014228983B2 publication Critical patent/AU2014228983B2/en
Priority to AU2018204879A priority Critical patent/AU2018204879A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
AU2014228983A 2013-03-15 2014-03-14 Toxoid, compositions and related methods Ceased AU2014228983B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018204879A AU2018204879A1 (en) 2013-03-15 2018-07-04 Toxoid, compositions and related methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793376P 2013-03-15 2013-03-15
US61/793,376 2013-03-15
PCT/US2014/029070 WO2014144594A1 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018204879A Division AU2018204879A1 (en) 2013-03-15 2018-07-04 Toxoid, compositions and related methods

Publications (2)

Publication Number Publication Date
AU2014228983A1 AU2014228983A1 (en) 2015-10-08
AU2014228983B2 true AU2014228983B2 (en) 2018-04-05

Family

ID=50489432

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014228983A Ceased AU2014228983B2 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods
AU2018204879A Abandoned AU2018204879A1 (en) 2013-03-15 2018-07-04 Toxoid, compositions and related methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018204879A Abandoned AU2018204879A1 (en) 2013-03-15 2018-07-04 Toxoid, compositions and related methods

Country Status (13)

Country Link
US (1) US20160030542A1 (enExample)
EP (1) EP2970400A1 (enExample)
JP (1) JP2016519671A (enExample)
KR (1) KR20150133771A (enExample)
CN (1) CN105308066A (enExample)
AR (1) AR095668A1 (enExample)
AU (2) AU2014228983B2 (enExample)
BR (1) BR112015023469A8 (enExample)
CA (1) CA2907156A1 (enExample)
HK (1) HK1213917A1 (enExample)
SG (1) SG11201507578PA (enExample)
TW (1) TW201518316A (enExample)
WO (1) WO2014144594A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510166YA (en) * 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
CN108003224A (zh) * 2017-12-20 2018-05-08 天康生物股份有限公司 一种多杀性巴氏杆菌毒素蛋白的纯化方法
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
AU2008280755B9 (en) 2007-07-26 2014-09-25 Sanofi Pasteur Limited Antigen-adjuvant compositions and methods
WO2009035707A1 (en) 2007-09-14 2009-03-19 Acambis Inc. Pharmaceutical compositions containing clostridium difficile toxoids a and b
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S W Rothman ET AL, "Differential cytotoxic effects of toxins A and B isolated from Clostridium difficile", Infection and immunity, (1984), pages 324 - 331 *

Also Published As

Publication number Publication date
BR112015023469A2 (pt) 2017-07-18
HK1213917A1 (zh) 2016-07-15
TW201518316A (zh) 2015-05-16
US20160030542A1 (en) 2016-02-04
EP2970400A1 (en) 2016-01-20
KR20150133771A (ko) 2015-11-30
WO2014144594A8 (en) 2014-11-13
BR112015023469A8 (pt) 2019-12-03
AU2018204879A1 (en) 2018-07-26
WO2014144594A1 (en) 2014-09-18
AR095668A1 (es) 2015-11-04
AU2014228983A1 (en) 2015-10-08
CN105308066A (zh) 2016-02-03
JP2016519671A (ja) 2016-07-07
SG11201507578PA (en) 2015-10-29
CA2907156A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
US20180028637A1 (en) Toxoid, Compositions and Related Methods
AU2018204879A1 (en) Toxoid, compositions and related methods
US20090060904A1 (en) Vegetarian Protein A Preparation and Methods Thereof
JP2016519671A5 (enExample)
US4702910A (en) Common antigen (PSC-A) to Pseudomonas aeruginosa which acts as an agent for pretecting Pseudomonas aeruginosa infection
US11926853B2 (en) Botulinum toxin producing method
NZ566871A (en) Protein A Production and Purification without Using Animal Derived Components involving staphylococcus aureus
CN107847576A (zh) 针对艰难梭状芽孢杆菌的免疫方法
EP0282965B1 (en) Treponema hyodysenteriae antigen and uses therefor
TW202325338A (zh) 氣腫疽梭菌疫苗及製備方法
RU2533815C1 (ru) Способ получения протективной белоксодержащей фракции бактерий
KR102903132B1 (ko) 보툴리누스 독소의 제조 방법
EP0420743A1 (fr) Vaccin protecteur contre l'hémophilose porcine
RU2285540C2 (ru) СПОСОБ ПОЛУЧЕНИЯ АНАТОКСИНА Bordetella pertussis
JP2019501874A (ja) 精製組換えコレラ毒素Ｂ（ｒＣＴＢ）及びその製剤の新規の製造方法
JPS60248623A (ja) 緑膿菌感染に対してワクチン活性を有するリポ糖蛋白ｐｓｃ―ａおよび緑膿菌ワクチン

Legal Events

Date Code Title Description
CB Opposition filed

Opponent name: WYETH, LLC

CH Opposition withdrawn

Opponent name: WYETH, LLC

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired